RecallHawk

NOREPINEPHRINE BITARTRATE IN SODIUM CHLORIDE (NOREPINEPHRINE BITARTRATE)

INFORLIFE

Summary

FDA approved NOREPINEPHRINE BITARTRATE IN SODIUM CHLORIDE (NOREPINEPHRINE BITARTRATE) by INFORLIFE. NDA (New Drug) approval (Labeling) on 2023-07-27. SOLUTION, INTRAVENOUS.

Details

Source

Drug Approval

External ID

NDA215700-2

Action Date

2023-07-27

Status

Approved

Category

drug

Product Code

NDA (New Drug)

Product Description

NOREPINEPHRINE BITARTRATE IN SODIUM CHLORIDE (generic: NOREPINEPHRINE BITARTRATE), SOLUTION, INTRAVENOUS. Application: NDA215700

Company

Context & Analysis

INFORLIFE has 3 FDA actions in our database.

Frequently Asked Questions

How often does INFORLIFE have FDA actions?

INFORLIFE has 3 FDA actions in our database, including 0 recalls and 0 device clearances.

Where can I find the official FDA record?

The official record is available on FDA.gov. Search for "NDA215700-2" on FDA.gov for the full record. You can also use the openFDA API to query this record programmatically.

Want to know the moment something like this happens?

Get alerts for drug

Related Actions